Coagulation factors are protein components of the blood which serve blood coagulation.
Search results 1 to 25 from a total of 89
| Name | Marketing Authorisation Holder | License Number | License Date | Further Information |
|---|---|---|---|---|
ADVATE |
Takeda Manufacturing Austria AG |
EU/1/03/271 | 02.03.2004 | |
|
Adynovi |
Baxalta Innovations GmbH, A |
EU/1/17/1247 | 08.01.2018 | |
|
Afstyla |
CSL Behring GmbH |
EU/1/16/1158 | 04.01.2017 | |
|
Alphanine 500 |
Grifols Deutschland GmbH |
6408.00.00 | 17.07.1985 | |
|
Alphanine 1000 |
Grifols Deutschland GmbH |
6408.01.00 | 17.07.1985 | |
|
Alprolix |
Swedish Orphan Biovitrum AB (publ) |
EU/1/16/1098 | 12.05.2016 | |
BeneFIX |
Pfizer Europe MA EEIG |
EU/1/97/047 | 27.08.1997 | |
|
Beriate 250 |
CSL Behring GmbH |
10505a/98-1 | 11.02.1998 | Rote-Hand-Brief: Beriate (09.08.2019) |
|
Beriate 500 |
CSL Behring GmbH |
10505a/98-2 | 11.02.1998 | Rote-Hand-Brief: Beriate (09.08.2019) |
|
Beriate 1000 |
CSL Behring GmbH |
10505a/98-3 | 11.02.1998 | Rote-Hand-Brief: Beriate (09.08.2019) |
Beriate 1000 |
CC-Pharma GmbH |
PEI.H.12077.02.1 | 06.05.2021 | |
|
Beriate 2000 |
CSL Behring GmbH |
10505a/98-4 | 11.12.2012 | Rote-Hand-Brief: Beriate (09.08.2019) |
Beriate 2000 |
Orifarm GmbH |
PEI.H.12092.02.1 | 19.04.2021 | |
Beriate 2000 |
CC-Pharma GmbH |
PEI.H.12077.01.1 | 10.03.2021 | |
|
Beriplex P/N 250 |
CSL Behring GmbH |
10500a/95 | 21.02.1996 | |
|
Beriplex P/N 500 |
CSL Behring GmbH |
10501a/95 | 21.02.1996 | |
|
Beriplex P/N 1000 |
CSL Behring GmbH |
10501a/95a | 26.01.2013 | |
Cevenfacta |
Laboratoire francais du Fractionement et des Biotechnologies, Frankreich |
EU/1/22/1664 | 15.07.2022 | |
|
Cluvot 250 I.E. |
CSL Behring GmbH |
PEI.H.11666.01.1 | 07.03.2014 | |
|
Cluvot 1250 I.E. |
CSL Behring GmbH |
PEI.H.11666.02.1 | 07.03.2014 | |
|
Coagadex |
Bio Products Laboratory Ltd., UK-Hertfordshire |
EU/1/16/1087 | 16.03.2016 | |
Cofact 500 |
Prothya Biosolutions Netherlands B.V. |
PEI.H.03453.02.1 | 31.08.2007 | |
|
Elocta |
Swedish Orphan Biovitrum AB (publ) |
EU/1/15/1046 | 19.11.2015 | |
Esperoct |
Novo Nordisk A/S, Dänemark |
EU/1/19/1374 | 20.06.2019 | |
|
Faktor VIII SDH INTERSERO 250 |
Intersero GmbH |
16844.00.00 | 06.11.1991 |
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 519 in BAnz AT 26.07.2024 B6.
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Updated: 26.07.2024
